Navigation Links
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
Date:9/25/2008

of complement in myocardial ischemia/reperfusion injury and antibody-mediated rejection in a mouse heterotopic heart transplant model

Carl Atkinson*, Yongquan Gong, Yuxiang Huang, Emily Pauling, Martin Goddard, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 196

Oral Presentation:

mAb171

Treatment with a highly inhibitory monoclonal antibody directed to the C3d ligand binding site on human CR2/CD21 suppresses antigen-specific immune responses in vivo

Liudmila Kulik*, Jonathan P. Hannan, Brigitte T. Huber, V. Michael Holers

Oct. 1, 2008, Animal models (Room: Montreal), 9:30 a.m. - 9:45 a.m., Oral 49

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Taligen's chief scientific officer Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit http://www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Compan
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
2. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
5. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
8. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
9. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
10. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
11. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sep. 04, 2015 ... addition of the "Stability Testing of Pharmaceuticals (London, ... offering. By attending this comprehensive two day ... design efficient stability studies that are suitable for global ... stability studies and manage stability samples and facilities ...
(Date:9/3/2015)... , Sept. 3, 2015 ... Potentials of New Drugs, Industry Changes and Emerging ... the human ovaries? Visiongain,s new study forecasts those ... growth in that industry. You also explore trends, ... Our report gives revenue predictions to 2025 ...
(Date:9/3/2015)... 2015 About self-monitoring blood glucose device ... electronic device. It consists of a glucose sensor ... levels through radiowaves from the sensor to a ... of self-monitoring blood glucose devices can improve self-management ... proper diabetes treatment. Technavio,s analysts forecast ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6Global Self-monitoring Blood Glucose Devices Market 2015-2019 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:9/4/2015)... ... September 04, 2015 , ... ... personal humidifying medical devices, announced its only mission and research focus: Water Life ... Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a result ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., (SWA) ... been selected for the Residential Award of Merit by the Connecticut Green Building ... from a highly competitive field of submissions, the net-zero energy residence will be ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... filtration products, has a Labor Day offer that cannot be passed up. ... stock up on necessary air and water filtration product replacements. Take advantage of ...
(Date:9/3/2015)... Wauwatosa, WI (PRWEB) , ... September 04, 2015 , ... ... the month of September. , "There are so many children and adults who ... in Wisconsin," says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... Get ready to feel good. That,s the,mantra for ... feel good these days. The national March of Dimes ... a debut fundraiser called,"Stork Tunes." Just in time for ... will fund the nonprofit,s efforts to give every baby ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ) ... at the Pacific,Research Center in Newark, California. Revance ... development and,commercialization of innovative biopharmaceutical products for the,aesthetic ... lease,more than 90,000 square feet at BioMed,s multi-tenant ...
... a leading global research,organization, announced that it has opened ... appointment of Dr. Alexey V. Kornilov as,General Manager of ... grow rapidly under the leadership of Alexey,V. Kornilov, MD ... Development brand. Dr. Kornilov brings over 10 years of ...
... At least twice, Holy See has failed to submit required reports, ... ... clergy pose current threat to children worldwide, ... group believes, NEW YORK, April 13 , What, At a ...
... Into Meeting to Attack RNs and ... Break Up Conference on Union Democracy, DEARBORN, ... tonight condemned a brutal,assault by busloads of purple cloaked staff ... of union members Saturday,night in Dearborn, Mi. and physically assaulted ...
... quickly in mice who exercised than in those who did ... to tumors, according to a new study by researchers in ... Center. , Our study showed that exercise led to significantly ... this mouse model, said Lee Jones, Ph.D., a researcher in ...
Cached Medicine News:Health News:Northwest Songwriter Dean Backholm Featured on National March of Dimes CD 2Health News:BioMed Realty Trust Announces 90,000 Square Foot Lease at Pacific Research Center 2Health News:BioMed Realty Trust Announces 90,000 Square Foot Lease at Pacific Research Center 3Health News:Chiltern Opens a New Office in Russia 2Health News:Clergy Abuse Victims Want UN to Investigate Vatican 2Health News:CNA/NNOC: RNs Condemn Violent Service Union Attack at Michigan Event 2Health News:CNA/NNOC: RNs Condemn Violent Service Union Attack at Michigan Event 3Health News:Exercise may lead to faster prostate tumor growth 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: